C. F. Xu
- Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery 24
- Biomedical Engineering top 0.5%
- Bone Tissue Engineering Materials 21
- Nanoplatforms for cancer theranostics 20
- Cancer Research top 2%
- MicroRNA in disease regulation 17
- Pharmaceutical Science top 1%
- Materials Chemistry top 2%
-
- Advanced biosensing and bioanalysis techniques 18
- RNA Interference and Gene Delivery 18
- RNA modifications and cancer 14
-
- Lung Cancer Diagnosis and Treatment 14
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Journal of the American Chemical Society (3 papers)Advanced Materials (10 papers)
- Partner nations
- ChinaAustraliaUnited States
In The Last Decade
C. F. Xu
237 papers receiving 7.7k citations
Hit Papers
Peers
Comparison fields: 5 of 157
- Biomaterials 1.4k
- Biomedical Engineering 2.7k
- Cancer Research 654
- Pharmaceutical Science 261
- Materials Chemistry 1.7k
Countries citing papers authored by C. F. Xu
This map shows the geographic impact of C. F. Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. F. Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. F. Xu more than expected).
Fields of papers citing papers by C. F. Xu
This network shows the impact of papers produced by C. F. Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. F. Xu. The network helps show where C. F. Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside C. F. Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2025 | 0 | |
| 5 | 2025 | 1 | |
| 6 | 2025 | 0 | |
| 7 | 2025 | 0 | |
| 8 | 2024 | 0 | |
| 9 | 2024 | 3 | |
| 10 | Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis managementbreakdown → | 2023 | 76 |
| 11 | 2023 | 13 | |
| 12 | Reprogramming Macrophage Polarization, Depleting ROS by Astaxanthin and Thioketal‐Containing Polymers Delivering Rapamycin for Osteoarthritis Treatmentbreakdown → | 2023 | 76 |
| 13 | 2023 | 4 | |
| 14 | 2023 | 2 | |
| 15 | 2021 | 60 | |
| 16 | 2021 | 10 | |
| 17 | 2021 | 62 | |
| 18 | 2020 | 58 | |
| 19 | 2019 | 162 | |
| 20 | Progressive Investigation on the Molecular Mechanism of Photosynthetic Oxygen Evolution | 2003 | 4 |
About C. F. Xu
C. F. Xu is a scholar working on Biomaterials, Cancer Research and Biomedical Engineering, having authored 262 papers that have together received 7.7k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (24 papers), Bone Tissue Engineering Materials (21 papers), Nanoplatforms for cancer theranostics (20 papers), Advanced biosensing and bioanalysis techniques (18 papers), RNA Interference and Gene Delivery (18 papers), MicroRNA in disease regulation (17 papers), RNA modifications and cancer (14 papers) and Lung Cancer Diagnosis and Treatment (14 papers). The work is most often cited by research in Biomaterials (1.4k citations), Biomedical Engineering (2.7k citations) and Cancer Research (654 citations). C. F. Xu has collaborated with scholars based in China, Australia and United States. Frequent co-authors include Chengzhong Yu, Chang Lei, Yannan Yang, Hongwei Zhang, Meihua Yu, Hao Song, Qingsong Ye, Yuzhi Fang, Owen Noonan and Jun Zhang. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Advanced Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.